Checkpoint Inhibitor-induced Liver Injury in patients with advanced melanoma and cutaneous squamous cell carcinoma: a single center experience
Mario Salvi(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Ketty Peris(Agostino Gemelli University Polyclinic), Lucia Di Nardo(Università Cattolica del Sacro Cuore), A. Grieco(Università Cattolica del Sacro Cuore), Antonio Liguori(Agostino Gemelli University Polyclinic), Laura Quattrini(Agostino Gemelli University Polyclinic), F. Brunetti(Università Cattolica del Sacro Cuore), Sebastiano Archilei(Università Cattolica del Sacro Cuore), Alessandro Di Stefani(University of Rome Tor Vergata)
Cited by 0
Related Papers
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
|British Journal of Dermatology|2020|590
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016
|European Journal of Cancer|2016|579
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores
|Journal of Hepatology|2020|361
Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline
|European Journal of Cancer|2009|316
Understanding the Molecular Genetics of Basal Cell Carcinoma
|International Journal of Molecular Sciences|2017|243